Evidence map›Paper›PMID 36094314›Full record

ArticleJournal of virology2022

The Epstein-Barr Virus Enhancer Interaction Landscapes in Virus-Associated Cancer Cell Lines.

Weiyue Ding, Chong Wang, Yohei Narita, Hongbo Wang, Merrin Man Long Leong, Alvin Huang, Yifei Liao, Xuefeng Liu, Yusuke Okuno, Hiroshi Kimura and 5 more

Open access · greenAbstract read
In one paragraph

Article in Journal of virology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
2.0field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 20 citations in OpenAlex.

  1. Article
  2. Epstein-Barr Virus-Associated T/NK-Cell Neoplasms.Journal of medical virology · 2026
    Review
  3. Article
  4. Epstein-Barr Virus Encoded lncRNAs Control the Viral Lytic Switch.bioRxiv : the preprint server for biology · 2025
    Article
  5. Chromatin Control of EBV Infection and Latency.Current topics in microbiology and immunology · 2025
    Article
  6. Article
  7. Article
  8. Article
  9. Viral remodeling of the 4D nucleome.Experimental & molecular medicine · 2024
    Review
  10. Article
  11. Article
  12. CRISPR-Cas-mediated transcriptional modulation: The therapeutic promises of CRISPRa and CRISPRi.Molecular therapy : the journal of the American Society of Gene Therapy · 2023
    Review
  13. Review
  14. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 5 institutions in 2 countries.

Weiyue Ding *Division of Infectious Diseases, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.
Chong Wang *Division of Infectious Diseases, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.
Yohei Narita *Division of Infectious Diseases, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.
Hongbo WangDivision of Infectious Diseases, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.
Merrin Man Long LeongDivision of Infectious Diseases, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.
Alvin HuangDivision of Infectious Diseases, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.
Yifei LiaoDivision of Infectious Diseases, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.
Xuefeng LiuComprehensive Cancer Center, Ohio State University, Columbus, Ohio, USA.
Yusuke OkunoDepartment of Virology, Nagoya City University Graduate School of Medicine, Nagoya, Aichi, Japan.
Hiroshi KimuraDepartment of Virology, Nagoya University Graduate School of Medicine, Nagoya, Aichi, Japan.ORCID 0000-0001-8063-5660
Benjamin GewurzDivision of Infectious Diseases, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.ORCID 0000-0002-3965-3418
Mingxian TengDepartment of Biostatistics and Bioinformatics, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, USA.ORCID 0000-0002-8536-8941
Shuilin JinPrecision Neurology Program, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.
Yoshitaka SatoDepartment of Virology, Nagoya University Graduate School of Medicine, Nagoya, Aichi, Japan.ORCID 0000-0002-8541-6413
Bo ZhaoDivision of Infectious Diseases, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.ORCID 0000-0002-8612-5597
Brigham and Women's Hospital · USNagoya University · JPMoffitt Cancer Center · USNagoya City University · JPThe Ohio State University · US

Funding

Epstein-Barr Virus Nuclear Proteins in B Cell Growth TransformationR01CA047006 · NCI · BRIGHAM AND WOMEN'S HOSPITAL · PI ZHAO, BO · 2002 to 2021
$12.1M
Targeting Epstein-Barr Virus super-enhancersR01AI123420 · NIAID · BRIGHAM AND WOMEN'S HOSPITAL · PI Bo Zhao · 2016 to 2026
$5.1M
Regulation of the Epstein-Barr Virus Lytic SwitchR01AI164709 · NIAID · BRIGHAM AND WOMEN'S HOSPITAL · PI Benjamin Elison Gewurz · 2021 to 2026
$3.1M
Epstein-Barr Virus nuclear antigen leader protein in transcription regulationK99DE030215 · NIDCR · BRIGHAM AND WOMEN'S HOSPITAL · PI WANG, CHONG · 2021 to 2022
$174k
NCI NIH HHS R01 CA047006NIAID NIH HHS R01 AI123420NIAID NIH HHS R01 AI164709NIDCR NIH HHS K99 DE030215
6 · The paper itself

Abstract

Epstein-Barr virus (EBV) persists in human cells as episomes. EBV episomes are chromatinized and their 3D conformation varies greatly in cells expressing different latency genes. We used HiChIP, an assay which combines genome-wide chromatin conformation capture followed by deep sequencing (Hi-C) and chromatin immunoprecipitation (ChIP), to interrogate the EBV episome 3D conformation in different cancer cell lines. In an EBV-transformed lymphoblastoid cell line (LCL) GM12878 expressing type III EBV latency genes, abundant genomic interactions were identified by H3K27ac HiChIP. A strong enhancer was located near the BILF2 gene and looped to multiple genes around BALFs loci. Perturbation of the BILF2 enhancer by CRISPR interference (CRISPRi) and CRISPR activation (CRISPRa) altered the expression of BILF2 enhancer-linked genes, including BARF0 and BALF2, suggesting that this enhancer regulates the expression of linked genes. H3K27ac ChIP followed by deep sequencing (ChIP-seq) identified several strong EBV enhancers in T/NK (natural killer) lymphoma cells that express type II EBV latency genes. Extensive intragenomic interactions were also found which linked enhancers to target genes. A strong enhancer at BILF2 also looped to the BALF loci. CRISPRi also validated the functional connection between BILF2 enhancer and BARF1 gene. In contrast, H3K27ac HiChIP found significantly fewer intragenomic interactions in type I EBV latency gene-expressing primary effusion lymphoma (PEL) cell lines. These data provided new insight into the regulation of EBV latency gene expression in different EBV-associated tumors.

Indexed as

Epstein-Barr Virus InfectionsHerpesvirus 4, HumanPlasmidsVirus LatencyCell Line, TumorEnhancer Elements, GeneticEpstein-Barr Virus Nuclear AntigensHumansMicroRNAsNeoplasmsViral ProteinsBARF1 protein, Human herpesvirus 4Epstein-Barr Virus Nuclear AntigensMicroRNAsViral Proteins3D genome organizationepisomeEpstein-Barr viruslatency

Identifiers

PMID36094314
PMCPMC9517713
OpenAlexW4295280959

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.